Sernova Corp. Expands Scientific Advisory Board

LONDON, ONTARIO--(Marketwire - October 19, 2010) - Sernova Corp. (TSX VENTURE: SVA), is pleased to announce the appointment of Dr. David Sutherland, MD, Ph.D. to the Corporation’s Scientific Advisory Board.

“Dr. Sutherland joining our Scientific Advisory Board follows the Company’s recent announcement of Dr. David Shapiro’s appointment and represents another key component in our strategy of advancing Sernova’s Cell Pouch System™ into Human Clinical Trials,” stated Dr. Philip Toleikis, Sernova’s President & CEO.

Dr. Sutherland, M.D., Ph.D. is a Professor, Transplantation Scientist and Clinician in the Division of Transplantation, Director of the Schulze Diabetes Institute and Dobbs Diabetes Research Chair within the Department of Surgery at the University of Minnesota where he oversees the largest clinical islet autotransplant program in the world.

In 1974, Dr. Surtherland pioneered islet transplantation by performing the world’s first clinical islet transplant.

Dr. Sutherland is a member of the executive committee of the Collaborative Islet Transplant Registry (CITR) and has served as president of the International Transplantation Society, the American Society of Transplant Surgeons, the Cell Transplant Society, and the International Pancreas and Islet Transplant Association. He is author or co-author on over 1500 publications.

“Sernova’s Cell Pouch System™ represents a potential opportunity to significantly optimize and simplify islet transplantation. In addition, the potential islet-sparing effect is highly attractive. I look forward to working with Sernova to advance the Cell Pouch System™ into human clinical trials,” Said Dr. Sutherland.

Sernova’s Cell Pouch System™ is a scalable medical device providing a natural “organ-like” environment for therapeutic cells. Once implanted under the skin, it develops into a tissue-engineered pancreas-like endocrine “organ” when infused with islets. The natural environment established by the Cell Pouch System™ is expected to conserve cell number, and promote natural function thereby increasing cell survival, while significantly increasing the number of treatable patients beyond those with severe disease.

Dr. Toleikis added, “Having both the pioneer of islet autograft transplant in Dr. Sutherland and the pioneer of the Edmonton Protocol in Dr. Shapiro associated with our company provides significant validation to our platform to deliver therapeutic cells through the Cell Pouch System™. We anticipate that their involvement with our Scientific Advisory Board will streamline the clinical development and commercialization of this important product.”

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System™ to provide a safe and efficacious environment for therapeutic cells and Sertolin™, a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova’s expectations are disclosed in Sernova’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.